Trials / Withdrawn
WithdrawnNCT00390091
Study of LJP 394 (Abetimus Sodium) in Lupus Patients
A Randomized, Double-Blind Study to Evaluate the Safety, Pharmacokinetic and Pharmacodynamic Effects of Abetimus Sodium in Patients With Systemic Lupus Erythematosus (SLE)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- La Jolla Pharmaceutical Company · Industry
- Sex
- All
- Age
- 12 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to assess the safety and pharmacodynamic effect of LJP 394 at doses of 100 mg, 300 mg and 900 mg on anti-dsDNA antibody levels in patients with SLE.
Detailed description
STUDY NOW INCORPORATED INTO PHASE 3 STUDY NCT00089804.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | abetimus sodium (LJP 394) |
Timeline
- Start date
- 2006-09-01
- First posted
- 2006-10-19
- Last updated
- 2015-09-01
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00390091. Inclusion in this directory is not an endorsement.